Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival

Area of Science:

• Medical Oncology
• Biostatistics
• Clinical Trial Design

Background:

• Minimizing radiation damage to critical organs during solid tumor treatment is a significant clinical challenge.
• Esophageal cancer radiation therapy poses risks to organs like the heart and lungs, with potential for complex toxicities.

Purpose of the Study:

• To introduce a novel Bayesian group sequential clinical trial design for comparing esophageal cancer radiation therapy modalities.
• The design aims to optimize treatment by considering both total toxicity burden (TTB) and progression-free survival.

Main Methods:

• Utilized a Bayesian group sequential design incorporating total toxicity burden (TTB) and progression-free survival.
• Modeled patient toxicities using a multivariate doubly stochastic Poisson point process with severity weights.
• Employed latent frailties for a multivariate outcome model and group sequential decision rules based on posterior means.

Main Results:

• The proposed Bayesian design demonstrated increased statistical power compared to conventional methods.
• The new design achieved a smaller mean sample size, indicating greater efficiency.
• The approach effectively integrates complex toxicity data and survival outcomes.

Conclusions:

• The developed Bayesian group sequential design offers a more powerful and efficient method for comparing radiation therapy modalities in esophageal cancer.
• This approach provides a robust framework for managing treatment-related toxicities and improving patient outcomes.
• The study highlights the potential of advanced statistical modeling in optimizing cancer treatment strategies.